Back to Agenda
Session 2: A Shared Vision for Patient Engagement: Stakeholder Perspectives
Session Chair(s)
Richard Klein
Director, Expanded Access Programs & Policy, Former FDA, Patient Liaison
GE2P2 Global Foundation, United States
The ultimate goal of patient engagement in the process of developing medical products is to achieve the best possible outcome for the patient. Patients, researchers, and regulators all share this vision, but each stakeholder has a unique perspective of the role of patient engagement in the process. Why is patient engagement important? What are its benefits? What specific efforts are key to effective engagement? What are the expected outcomes of successful patient engagement? A true, functioning partnership among the stakeholders must be based on mutual understanding of these perspectives. In this session, patient group, industry, and regulatory agency leaders will discuss their views on the need for patient engagement and expected outcomes.
Speaker(s)
Patient Groups' Perspective
Patricia Furlong, BSN
Parent Project Muscular Dystrophy, United States
Founding President and Chief Executive Officer
Laurie Letvak, MD
Novartis Pharmaceuticals Corporation, United States
Head Clinical Policy and Medical Ethics
Regulators' Perspective
Theresa Mullin, PhD
FDA, United States
Associate Center Director - Strategic Initiatives, CDER
Panel Discussion
All Session Speakers, United States
Have an account?